$GNTX

Thrivent Financial for Lutherans Sells 44,779 Shares of Gentex Corporation $GNTX

Thrivent Financial for Lutherans reduced its Gentex (GNTX) stake by 30.4% in Q4, selling 44,779 shares and holding 102,523 shares worth $2.386M, according to HoldingsChannel and the firm’s SEC filing. Gentex reported Q1 EPS of $0.48 vs $0.44 expected on revenue of $675.44M. Analysts’ consensus is Hold with a $26.83 target.

Original reporting
Published May 26, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 11:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Thrivent Financial for Lutherans Sells 44,779 Shares of Gentex Corporation $GNTX — source image
Decision brief

The 30-second read

$GNTXNeutralMed
01

Why it matters

Trading focus is on ownership/insider flow signals (institutional cut and director sales) contrasted with operational performance (EPS and revenue beat, YoY revenue growth).

02

Market read

For GNTX, the key market signal is institutional de-risking plus recent insider selling, tempered by a recent earnings beat and positive YoY revenue growth.

03

What to watch

Analyst targets remain broadly supportive (multiple price objectives in the mid/high-$20s), and the article doesn’t show whether the trimmed shares were sold into strength or for portfolio liquidity needs.

Relevance 8/10Timing: Positioning/flow signal is immediate; earnings were reported on Apr 24 and may already be partially priced.

Background

The piece compiles 13F-style institutional ownership changes and SEC insider sale disclosures for Gentex, alongside recent earnings and analyst notes.

Company-level read

Ticker impact

$GNTXNeutralMedium confidence
Context

Thrivent Financial for Lutherans trimmed its Gentex stake by 30.4% in Q4, signaling institutional repositioning in GNTX auto-parts exposure.

Expected impact

Choppy-to-soft trading is plausible near term; upside likely requires follow-through on earnings momentum rather than positioning flows.

Evidence & confidence

The article cites a 30.4% stake cut by a large institutional holder and director sales, but also reports Gentex beat on EPS and revenue growth year-over-year.

Market effects

Read-through for auto-parts/ADAS suppliers: institutional rotation can affect sentiment even when company-specific results are improving.

No explicit regional catalyst; impact is primarily US-listed sentiment around GNTX.

Gentex is global, but the article provides no geography-specific demand or regulatory changes.

Counterpoint

The institutional trim could be risk-management or rebalancing rather than a bearish view on Gentex’s fundamentals, especially given the earnings beat and revenue growth.

Key entities

  • Gentex Corporation

    Auto parts/ADAS supplier; subject of institutional stake trimming and director insider sales, with recent earnings beat.

  • Thrivent Financial for Lutherans

    Trimmed its Gentex position by 30.4% in Q4 per the article.

  • Joseph B. Anderson, Jr.

    Director who sold 5,939 shares on May 15 at an average $22.98.

  • Richard O. Schaum

    Director who sold 4,815 shares on Apr 30 at an average $23.31.

Related articles

$GNTXMedAI 8/10

Gentex Eyes $7B Revenue Path With Auto Tech, VOXX and Contract Manufacturing

Gentex (GNTX) aims for $4.5B-$7B revenue over 10 years, diversifying from auto mirrors to tech, VOXX, and manufacturing. It expects $2.5B revenue in 2025, with growth from Full Display Mirrors, driver-monitoring systems, and new products. VOXX acquisition exceeded targets, with improved margins and strategic value. Non-automotive revenue hit 14% in Q2. Gentex plans to expand contract manufacturing, targeting $1B-$2B revenue. The company returned $4.3B to shareholders over a decade and aims for $

$GNTXMed

GENTEX CORP (GNTX): Results of Operations and Financial Condition

GENTEX CORP (GNTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit99106302026.htm EX-99.1 Document Exhibit 99.1 GENTEX REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS ZEELAND, MI -- (GLOBE NEWSWIRE - July 24, 2026) - Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass, fire prote

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.